-
1Academic Journal
Authors: E. A. Nikolaeva, A. S. Krylov, A. D. Ryzhkov, T. M. Geliashvili, A. V. Pavlova, A. Yu. Goryainova, R. A. Murashko, Е. А. Николаева, А. С. Крылов, А. Д. Рыжков, Т. М. Гелиашвили, А. В. Павлова, А. Ю. Горяинова, Р. А. Мурашко
Source: Cancer Urology; Том 20, № 2 (2024); 74-86 ; Онкоурология; Том 20, № 2 (2024); 74-86 ; 1996-1812 ; 1726-9776
Subject Terms: радионуклидная терапия, metastatic castration-resistant prostate cancer, quantitative single-photon emission computed tomography/computed tomography, radium-223 dichloride, radionuclide therapy, метастатический кастрационно-резистентный рак предстательной железы, количественная однофотонная эмиссионная компьютерная томография, совмещенная с компьютерной томографией, дихлорид радия-223
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1762/1547; Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI:10.1056/NEJMoa040720; Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270–3. DOI:10.1016/j.eururo.2013.10.055; Smith H.S. Painful osseous metastases. Pain Physician 2011;14(4):E373–403.; Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s–9s. DOI:10.1158/1078-0432.CCR-06-0931; Tait C., Moore D., Hodgson C. et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progressionfree and overall survival. BJU Int 2014;114(6b):E70–3. DOI:10.1111/bju.12717; Riihimäki M., Thomsen H., Brandt A. et al. What do prostate cancer patients die of? Oncologist 2011;16(2):175–81. DOI:10.1634/theoncologist.2010-0338; Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71(4):630–42. DOI:10.1016/j.eururo.2016.08.002; Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI:10.1056/NEJMoa1213755; Sartor O., Coleman R., Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738–46. DOI:10.1016/S1470-2045(14)70183-4; Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15(12):1397–406. DOI:10.1016/S1470-2045(14)70474-7; Nilsson S., Cislo P., Sartor O. et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 2016;27(5):868–74. DOI:10.1093/annonc/mdw065; Parker C., Finkelstein S.E., Michalski J.M. et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol 2016;70(5):875–83. DOI:10.1016/j.eururo.2016.06.002; Николаева Е.А., Тарачкова Е.В., Шейх Ж.В. и др. Обзор методов визуализации для оценки ответа на лечение метастазов в костях при раке предстательной железы и молочной железы. Кремлевская медицина. Клинический вестник 2022;3:107–14. DOI:10.26269/tvby-7e26; Helyar V., Mohan H.K., Barwick T. et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010;37(4):706–13. DOI:10.1007/s00259-009-1334-3; Vogelzang N.J., Coleman R.E., Michalski J.M. et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer 2017;15(1):42–52.e8. DOI:10.1016/j.clgc.2016.07.027; Etchebehere E.C., Araujo J.C., Fox P.S. et al. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med 2015;56(8):1177–84. DOI:10.2967/jnumed.115.158626; Ulmert D., Kaboteh R., Fox J.J. et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 2012;62(1): 78–84. DOI:10.1016/j.eururo.2012.01.037; Fosbøl M.Ø., Petersen P.M., Kjaer A., Mortensen J. 223Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity. J Nucl Med 2018;59(4):596–602. DOI:10.2967/jnumed.117.195677; Shariftabrizi A., Kothari S., George S. et al. Optimization of radium-223 treatment of castration-resistant prostate cancer based on the burden of skeletal metastasis and clinical parameters. Oncologist 2023;28(3):246–51. DOI:10.1093/oncolo/oyac245; Николаева Е.А., Крылов А.С., Рыжков А.Д. и др. Количественная оценка методом ОФЭКТ/КТ эффективности радионуклидной терапии хлоридом радия-223 костных метастазов при метастатическом кастрационно-резистентном раке предстательной железы. Онкологический журнал: лучевая диагностика, лучевая терапия 2022;5(3):29–42. DOI:10.37174/2587-7593-2022-5-3-29-42; Shore N.D. Radium-223 dichloride for metastatic castrationresistant prostate cancer: the urologist’s perspective. Urology 2015;85(4):717–24. DOI:10.1016/j.urology.2014.11.031; Gillessen S., Omlin A., Attard G. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015;26(8):1589–604. DOI:10.1093/annonc/mdv257; CTCAE. National Cancer Institute Enterprise Vocabulary Services website. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/About.html (accessed 15 December 2023).; Asselah J., Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: questions of choice. Can Urol Assoc J 2013;7(1–2 Suppl 1):S11–7. DOI:10.5489/cuaj.274; Sathianathen N.J., Lamb A., Nair R. et al. Updates of prostate cancer staging: prostate-specific membrane antigen. Investig Clin Urol 2016;57(Suppl 2):S147–54. DOI:10.4111/icu.2016.57.S2.S147; Lowrance W.T., Roth B.J., Kirkby E. et al. Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 2016;195(5):1444–52. DOI:10.1016/j.juro.2015.10.086; Parker C., Gillessen S., Heidenreich A., Horwich A. ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v69–77. DOI:10.1093/annonc/mdv222; Saad F., Chi K.N., Finelli A. et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9(3–4):90–6. DOI:10.5489/cuaj.2526; Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(3s2):540–55. DOI:10.18027/2224-5057-2021-11-3s2-33; Smith M., Parker C., Saad F. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol 2019;20(10):e559]. Lancet Oncol 2019;20(3):408–19. DOI:10.1016/S1470-2045(18)30860-X; Choudhury A.D., Kwak L., Cheung A. et al. Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2021;39(6_suppl):98. DOI:10.1200/JCO.2021.39.6_suppl.98; Sternberg C.N., Saad F., Graff J.N. et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol 2020;31(2):257–65. DOI:10.1016/j.annonc.2019.10.025; Carles J., Alonso-Gordoa T., Mellado B. et al. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: a single-arm phase II trial. Eur J Cancer 2022;173:317–26. DOI:10.1016/j.ejca.2022.06.057; Marshall C.H., Fu W., Wang H. et al. Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bonemetastatic castration-resistant prostate cancer. Clin Cancer Res 2021;27(6):1623–30. DOI:10.1158/1078-0432.CCR-20-4476; Morris M.J., Loriot Y., Sweeney C.J. et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/ randomised phase 2a trial. Eur J Cancer 2019;114:107–16. DOI:10.1016/j.ejca.2019.04.007; Darolutamide with radium-223 or placebo and the effect on radiological Progression-free survival for patients with mCSPC (CARE). ClinicalTrials.gov. ID NCT05771896. Available at: https://clinicaltrials.gov/study/NCT05771896; Kostos L., Buteau J.P., Yeung T. et al. AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med (Lausanne) 2022;9:1059122. DOI:10.3389/fmed.2022.1059122; Pezaro C.J., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65:270–3. DOI:10.1016/j.eururo.2013.10.055; Bosch D., van der Velden K.J.M., Oving I.M. et al. The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients. Annals of Oncology 2023;34(Suppl 2): 987–8. DOI:10.1016/j.annonc.2023.09.2771; Carles J., Castellano D., Méndez-Vidal M.J. et al. Circulating tumor Cells as a biomarker of survival and response to Radium-223 therapy: experience in a cohort of patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16(6):e1133–9. DOI:10.1016/j.clgc.2018.07.013; Iizuka J. Evaluating radium-223 response in metastatic castrationresistant prostate cancer with imaging. Asia Pac J Clin Oncol 2018;14(Suppl 5):16–23. DOI:10.1111/ajco.13058; Scher H.I., Morris M.J., Stadler W.M. et al. Prostate cancer clinical trials working group 3. Trial design and objectives for castrationresistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402–18. DOI:10.1200/JCO.2015.64.2702; https://oncourology.abvpress.ru/oncur/article/view/1762